参芪消积方联合卡瑞利珠单抗及阿帕替尼治疗肝郁脾虚型中晚期肝癌临床疗效及安全性分析  

Clinical efficacy and safety analysis of Senqi Xiaoji Formula combined with karelizumab and apatinib in the treatment of intermediate and advanced hepatocellular carcinoma

作　　者：陈果 卢会琴 王叶鹏 周振华[3] CHEN Guo;LU Hui-qin;WANG Ye-peng;ZHOU Zhen-hua(Oncology Department,Anhui Hospital,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Hefei Anhui,230031,China;不详)

机构地区：[1]上海中医药大学附属曙光医院安徽医院肿瘤科,安徽合肥230031 [2]解放军第82医院肿瘤科 [3]上海中医药大学附属曙光医院肝病科

出　　处：《中西医结合肝病杂志》2024年第8期683-686,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：安徽省自然科学基金项目(No.2308085MH293);安徽省高校科学研究基金重点项目(No.2023AH050848)。

摘　　要：目的:探讨参芪消积方联合卡瑞利珠单抗及阿帕替尼治疗中晚期肝郁脾虚型肝细胞癌的临床疗效及安全性。方法:通过回顾性分析,选取74例肝郁脾虚型中晚期肝细胞癌患者分为研究组和对照组,各37例。对照组患者行“卡瑞利珠单抗及阿帕替尼”方案治疗,研究组患者在对照组治疗基础上加用参芪消积方。分析两组患者中医疗效指标、临床疗效、肝功能、甲胎蛋白(AFP)、卡式评分(KPS)、不良反应发生率及总生存期。结果:治疗2个月后,研究组患者的临床疗效、总生存期、KPS评分优于对照组(P<0.05);两组患者治疗后的肝功能、中医疗效指标、AFP均较治疗前有改善,但研究组患者效果更显著(P<0.05),且研究组患者不良反应发生率明显低于对照组(P<0.05)。结论:参芪消积方联合卡瑞利珠单抗及阿帕替尼治疗肝郁脾虚型中晚期肝细胞癌患者有明确的临床疗效,能延长患者生存周期,提高患者生活质量,值得临床推广使用。Objective:Exploring the clinical efficacy and safety of Shenqi Xiaoji Formula combined with Karelizumab and Apatinib in the treatment of advanced hepatocellular carcinoma.Methods:A total of 74 patients with middle and advanced stage hepatocellular carcinoma of the liver depression and spleen deficiency type were selected and divided into a study group and a control group,with 37 cases in each.The control group was treated with the"Camrelizumab and Apatinib"regimen,while the study group was additionally treated with the Shenqi Xiaoji Formula on the basis of the control group's treatment.The therapeutic effects of the two groups were analyzed in terms of TCM efficacy indicators,clinical efficacy,liver function,alpha-fetoprotein(AFP)levels,Karnofsky Performance Status(KPS),adverse reaction incidence,and overall survival time.Results:After 2 months of treatment,the clinical efficacy,overall survival,and KPS score of the study group were better than those of the control group(P<0.05).The liver function,traditional Chinese medicine efficacy indicators,and AFP of the two groups of patients improved after treatment,with the study group showing more significant improvement(P<0.05),and the incidence of adverse reactions in the study group was significantly lower than that in the control group(P<0.05).Conclusion:The combination of Shenqi Xiaoji Formula,Karelizumab,and Apatinib has a clear clinical efficacy in the treatment of advanced hepatocellular carcinoma patients with liver depression and spleen deficiency type.It can prolong the life cycle and improve quality of life,and is worthy of clinical promotion and use.

关 键 词：参芪消积方 卡瑞利珠单抗 阿帕替尼 肝细胞癌 肝郁脾虚型 

分 类 号：R259[医药卫生—中西医结合]